Analyst Price Target is $8.00
▲ +810.02% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cingulate in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 810.02% upside from the last price of $0.88.
Current Consensus is
Hold
The current consensus among 3 contributing investment analysts is to hold stock in Cingulate. This Hold consensus rating has held steady for over two years.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Read More